Vertaling van "regarding the development " (Nederlands → Frans) :

The role of the Central Working Group is to take decisions together with the Chief Executive Officer regarding the development of the FAMHP and to set priorities.
The role of the Central Working Group is to take decisions together with the Chief Executive Officer regarding the development of the FAMHP and to set priorities.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.
This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.

In December 2008 the Homeopathic and Herbal Medicinal Products Unit also published circular 533 regarding the notification of traditional herbal medicines. Finally, a specific database was developed for this.
In December 2008 the Homeopathic and Herbal Medicinal Products Unit also published circular 533 regarding the notification of traditional herbal medicines. Finally, a specific database was developed for this.

The Federal Agency for Medicines and Health Products faced numerous challenges in 2007: constructing a dynamic and efficient public service thanks to the newly acquired autonomy and transparent and professional management; developing into an institution with a national and international reputation; and becoming a learning organisation, capable of meeting people’s expectations with regard to public health.
The Federal Agency for Medicines and Health Products faced numerous challenges in 2007: constructing a dynamic and efficient public service thanks to the newly acquired autonomy and transparent and professional management; developing into an institution with a national and international reputation; and becoming a learning organisation, capable of meeting people’s expectations with regard to public health.

This is the reason why our general recommendation is that the authorities should develop a large-scale and coherent care programme regarding the issue of depression and suicide.
C’est pourquoi, notre recommandation globale est que les autorités développent un large programme de soins cohérent autour de la problématique de la dépression et du suicide.

The operating income margin of 31.9% of net sales was impacted by an impairment charge in R&D of USD 152 million after discontinuation of PTZ601, an anti-infective development project, while an asset write-up in Cost of Goods Sold of USD 100 million and an exceptional settlement gain in Other Income of USD 42 million were both related to the recent settlement with Teva regarding Famvir.
La marge opérationnelle de 31,9% du chiffre d’affaires net a été impactée par une charge d’un montant d’USD 152 millions pour perte de valeur en R&D après l’interruption du projet PTZ601 – un antiinfectieux en cours de développement – par la réévaluation d’un actif à hauteur d'USD 100 millions dans le coût des ventes et par un gain exceptionnel d’USD 42 millions dans les autres produits, tous deux liés au règlement conclu récemment avec Teva concernant Famvir.